NYSE: TWTR Investor Notice: Deadline in Lawsuit for Twitter Investors that SOLD over $200,000 worth of NYSE: TWTR shares between May and October 2022 announced by the Shareholders Foundation
14 nov. 2022 07h15 HE
|
Shareholders Foundation, Inc.
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced that a deadline is coming up on December 12th in the lawsuit that was filed against Elon Musk by an investor...
Deadline in Lawsuit for NYSE: TWTR Investors that SOLD over $200,000 worth of Twitter, Inc. shares between May and October 2022 announced by the Shareholders Foundation
01 nov. 2022 07h35 HE
|
Shareholders Foundation, Inc.
SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced that a deadline is coming up on December 12th in the lawsuit that was filed against Elon Musk by an investor...
Notice: Deadline in Lawsuit coming up and NYSE: TWTR Investors that SOLD over $250,000 worth of Twitter, Inc. shares between May and October 2022 should contact the Shareholders Foundation
27 oct. 2022 07h45 HE
|
Shareholders Foundation, Inc.
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced that a deadline is coming up in the lawsuit that was filed against Elon Musk by an investor who SOLD shares...
NYSE: TWTR Investors that SOLD over $100,000 worth of Twitter, Inc. shares between May and October 2022 should contact the Shareholders Foundation in connection with Lawsuit filed against Elon Musk
17 oct. 2022 08h15 HE
|
Shareholders Foundation, Inc.
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced that an investor who SOLD shares of Twitter, Inc. (NYSE: TWTR) filed a lawsuit against Elon Musk. Investors...
Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health
06 oct. 2022 12h51 HE
|
Optimi Health Corp.
Highlights: The safe supply of psychedelic drug products manufactured at a GMP-level is critical in treating serious mental health issues. Minister of Mental Health and Addictions, the Honourable...
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada
22 sept. 2022 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health...
Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History
08 sept. 2022 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed...
Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global
07 sept. 2022 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health...
Optimi Health Provides Progress Report On Year Of Commercialization
01 sept. 2022 09h00 HE
|
Optimi Health Corp.
Company set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertise VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:...
Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center
30 août 2022 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health...